SOPHIA ANTIPOLIS, FRANCE--(Marketwire - January 08, 2008) - NicOx S.A. (Euronext Paris: COX) today announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research in the field of ophthalmology. This one-year extension of the research phase of the agreement will result in NicOx receiving EUR 3 million in research funding in March 2008 and prolongs Pfizer’s option to license resulting compounds until May 2009.
